Tchaikapharma High Quality Medicines AD

Tchaikapharma High Quality Medicines AD maintains a conservative capital structure, with a debt-to-equity ratio of 0.1, indicating minimal reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 5.46, suggesting strong short-term liquidity. However, the firm's net cash position is negative after subtracting total debt, signaling potential near-term liquidity constraints.

Profitability metrics show a return on equity (ROE) of 1.38% and a return on assets (ROA) of 1.19%, both below the typical thresholds for high-margin pharmaceutical firms. The operating margin, calculated as operating income of 1,810,000 BGN on revenue of 13,361,000 BGN, yields a margin of 13.55%, which is in line with the industry median for mid-sized pharmaceutical companies.

The company's revenue is concentrated in a single geographic market, primarily Bulgaria, with no disclosed international operations or revenue diversification. This concentration increases exposure to local economic and regulatory shifts. No segment-specific revenue breakdown is available, but the firm operates as a single business unit focused on pharmaceuticals.

Growth trajectory is modest, with no disclosed revenue growth rates or forward-looking guidance. The firm's free cash flow of 2,088,000 BGN supports operational flexibility but lacks clear reinvestment or expansion plans. No recent acquisitions or new product launches are reported in the latest financial filings.

Risk factors include a medium liquidity risk due to the negative net cash position and a low dilution risk, as shares outstanding remain unchanged between basic and diluted counts. No recent equity offerings or dilutive events are reported, and the firm has not disclosed any plans for capital raising.

No recent events, such as earnings calls, regulatory filings, or press releases, are available in the latest data. The firm's financial disclosures are limited to standard annual reporting, with no additional commentary on strategic direction or market positioning.

Revenue grew 20.3% year-over-year to 64.1 million BGN, demonstrating strong top-line expansion momentum.

Net income surged 33.9% to 6.0 million BGN, outpacing revenue growth and indicating operating leverage.

Free cash flow increased 58.0% to 7.6 million BGN, providing robust liquidity for future investments.

The debt-to-equity ratio of 0.1 is well below the cohort median of 0.18, ensuring a conservative capital structure.

The company faces high credit risk, which could impair financial stability or increase borrowing costs significantly.

Cash conversion ratio of 0.86 is below the cohort median of 0.95, suggesting weaker earnings quality.

Medium liquidity risk may constrain the company's ability to meet short-term obligations during market stress.

Return on assets of 1.2% remains low, reflecting limited efficiency in generating profits from total assets.